scholarly journals The experience of domestic antiviral agents, and some of own approaches in the treatment of chronic hepatitis C in adults

2015 ◽  
Vol 20 (3) ◽  
pp. 4-10
Author(s):  
V. A Borisov ◽  
B. I Sanin ◽  
S. E Samsonova ◽  
E. N Arutyunyan ◽  
D. B Golubeva ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Gradual Increase ◽  
Antiviral Agents ◽  
Nucleoside Analogs ◽  
Antiviral Drugs ◽  
Weekly Dose ◽  
Glycyrrhizinic Acid ◽  
Cell Immunity

In the management of 148 adult patients with chronic hepatitis C (CHC) of both sexes without special selection (taken into account only absolute contraindications to its performance) there were used domestic basic antiviral drugs - BAD\ (short-living interferons (IFN) a, interferon inducers and nucleoside analogues) in parallel with additional antiviral drugs (drug glycyrrhizinic acid or amantadine) and maintenance therapy (stimulators of T-cell immunity and means of correction of side effects). Treatment was carried out in the framework of the developed complex of principles and approaches including in part, the formation of the starting average weekly dose of interferon IFN with accounting of the character of interferon status of the patient, a gradual increase in the average weekly dose of interferon IFN during the course of therapy, the delayed use of nucleoside analogs and others. As a result, against the background of a significant reduction in financial expenses and the aggressiveness of treatment the stable positive therapeutic outcome in the general population ofpatients occurred in 92.6%, with 87.2% in patients with genotype (G) 1.

scholarly journals Hepatitis C virus vaccine development: old challenges and new opportunities

2015 ◽  
Vol 2 (3) ◽  
pp. 285-295 ◽  
Author(s):  
Dapeng Li ◽  
Zhong Huang ◽  
Jin Zhong
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Vaccine Development ◽  
Rna Virus ◽  
Antiviral Agents ◽  
Resistance Mutations ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Hepatitis C virus (HCV), an enveloped positive-sense single-stranded RNA virus, can cause chronic and end-stage liver diseases. Approximately 185 million people worldwide are infected with HCV. Tremendous progress has been achieved in the therapeutics of chronic hepatitis C thanks to the development of direct-acting antiviral agents (DAAs), but the worldwide use of these highly effective DAAs is limited due to their high treatment cost. In addition, drug-resistance mutations remain a potential problem as DAAs are becoming a standard therapy for chronic hepatitis C. Unfortunately, no vaccine is available for preventing new HCV infection. Therefore, HCV still imposes a big threat to human public health, and the worldwide eradication of HCV is critically dependent on an effective HCV vaccine. In this review, we summarize recent progresses on HCV vaccine development and present our views on the rationale and strategy to develop an effective HCV vaccine.

scholarly journals Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents

PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0209216 ◽  
Author(s):  
Alessandro Gualerzi ◽  
Mattia Bellan ◽  
Carlo Smirne ◽  
Margherita Tran Minh ◽  
Cristina Rigamonti ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Insulin Sensitivity ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Diabetic Patients ◽  
Direct Antiviral Agents

Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review

2018 ◽  
Vol 13 (5) ◽  
pp. 775-790 ◽  
Author(s):  
Eleonora Tamborini Permunian ◽  
Lorenzo Gervaso ◽  
Victor Gerdes ◽  
Lorenzo Moja ◽  
Luigina Guasti ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Antiviral Drugs ◽  
Vascular Events ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document